Table S2. Proportion of patients who received RE within and beyond recommended guidelines.
| Parameter | CTCAE grade† | Values | N (%) patients |
|---|---|---|---|
| Total bilirubin (mg/dL) | 0 | ≤1.3 | 556 (94.0) |
| 1 | >1.3–1.95 | 22 (4.0) | |
| 2 | >1.95–3.9 | 13 (2.0) | |
| 3 | >3.9–13.0 | 1 (0.2) | |
| 4 | >13.0 | 1 (0.2) | |
| Albumin (g/dL) | 0 | ≥3.5 | 392 (66.0) |
| 1 | <3.5–3.0 | 127 (21.0) | |
| 2 | <3.0–2.0 | 64 (11.0) | |
| 3 | <2.0 | 8 (1.0) | |
| ALT (U/L) | 0 | ≤40 | 409 (70.0) |
| 1 | >40–100 | 150 (26.0) | |
| 2 | >100–200 | 22 (4.0) | |
| 3 | >200–800 | 2 (0.3) | |
| 4 | >800 | 1 (0.2) | |
| AST (U/L) | 0 | ≤35 | 296 (50.0) |
| 1 | >35–87.5 | 243 (41.0) | |
| 2 | >87.5–175 | 42 (7.0) | |
| 3 | >175–700 | 9 (1.0) | |
| Alk phosph (U/L) | 0 | ≤126 | 241 (41.0) |
| 1 | >126–315 | 252 (43.0) | |
| 2 | >315–630 | 81 (14.0) | |
| 3 | >630–2,520 | 18 (3.0) | |
| Creatinine (mg/dL) | 0 | ≤1.4 | 569 (96.0) |
| 1 | >1.4–2.1 | 21 (3.0) | |
| 2 | >2.1–4.2 | 3 (0.5.) | |
| 3 | >4.2–8.4 | 2 (0.3) | |
| 4 | >8.4 | 0 | |
| Hemoglobin (g/dL) | 0 | ≥12.0 | 356 (60.0) |
| 1 | <12.0–10.0 | 180 (30.0) | |
| 2 | <10.0–8.0 | 54 (9.0) | |
| 3 | <8.0–6.5 | 4 (1.0) |
†, CTCAE version 3.0. CTCAE, Common Toxicity Criteria Adverse Events; ALT, alanine transaminase; AST, aspartate aminotransferase; Alk phosph, alkaline phosphatase.